Dr. Schlossman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
40 Landsdowne Street
Cambridge, MA 02139Phone+1 857-600-3421
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1992 - 1995
MedStar Health/Georgetown University HospitalFellowship, Hematology and Medical Oncology, 1991 - 1992
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1988 - 1991
Tufts University School of MedicineClass of 1988
Certifications & Licensure
MA State Medical License 1992 - 2025
NY State Medical License 1989 - 1992
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma Start of enrollment: 2008 May 01
- Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma Start of enrollment: 2012 Mar 01
Publications & Presentations
PubMed
- 478 citationsMolecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.Teru Hideshima, Constantine S. Mitsiades, Masaharu Akiyama, Toshiaki Hayashi, Dharminder Chauhan
Blood. 2003-02-15 - 102 citationsAntimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235Douglas W. McMillin, Melissa G. Ooi, Jake Delmore, Joseph Negri, Patrick Hayden
Cancer Research. 2009-07-15 - 599 citationsPanobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: ...Jesús F. San-Miguel, V. Hungria, Sung-Soo Yoon, Meral Beksac, Meletios A. Dimopoulos
The Lancet. Oncology. 2014-10-01
Abstracts/Posters
- Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of OncoproteinsRobert L. Schlossman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple MyelomaRobert L. Schlossman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Long-Term Proteasome Inhibitor (PI) Therapy in Community Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (Btz)-Based to Ixazo...Robert L. Schlossman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoprotein...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
